AdvanCell
PrivateLast Round
Series D
Jul 15, 2026
Total Funding Raised
$786.96M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
AdvanCell is a clinical-stage radiopharmaceutical company that develops targeted alpha therapies for cancer treatment using a proprietary Lead-212 platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AdvanCell Comparables
Compare AdvanCell with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ARTBIO | 89% | |
| Alpha-9 Oncology | 87% | |
| Convergent Therapeutics | 85% |
AdvanCell Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jul 15, 2026 | ||||
| Grant | May 9, 2026 | ||||
| Grant | Apr 14, 2025 | ||||
| Series C | Feb 3, 2025 | ||||
| Series D | Jul 15, 2024 | ||||
Grant | Jul 5, 2023 |
Key People
Founding team and executive leadership
AdvanCell Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series D |
| SymBiosis Capital Management | Series D, Series C |
| SV Health Investors | Series D, Series C |
| Time BioVentures | Series D |
| Ally Bridge Group | Series D |
| Eventide Funds | Series D |
| Morningside Ventures | Series D, Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 14, 2026
Open roles increased to 16, 2.4x the trailing average.
- Aug 23, 2026
Grew 18% QoQ, from 85 to 100 employees.
Recent news
Latest coverage and updates
- expands_offices_toSep 17, 2026
AdvanCell Pty Ltd. expanded offices to Boston, Massachusetts, United States, Northern America, Americas on Sep 17th '26.
- hiresSep 16, 2026
AdvanCell Pty Ltd. hired Sean Cassidy as Chief Financial Officer on Sep 16th '26.
- is_developingJul 27, 2026
AdvanCell Pty Ltd. is developing related type of treatment using lead-212, which releases alpha particles over a short distance. on Jul 27th '26.
- expands_facilitiesJul 17, 2026
AdvanCell Pty Ltd. expands facilities to United States, Northern America, Americas.
- receives_financingJul 17, 2026
AdvanCell Pty Ltd. received financing of $315M in Series D on Jul 17th '26.
AdvanCell Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about AdvanCell's valuation, stock price, and market status.
Is AdvanCell a public or private company?
AdvanCell is a private company.
What is the current stock price of AdvanCell?
AdvanCell is a private company with no public stock price. No recent secondary market data is available.
How much is AdvanCell worth (valuation)?
Valuation information for AdvanCell is not publicly available.
Can I buy AdvanCell stock?
AdvanCell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was AdvanCell's last funding round?
AdvanCell's most recent funding round was Grant on April 14, 2025.
Who are the main investors in AdvanCell?
Key investors in AdvanCell include SymBiosis Capital Management, SV Health Investors, Abingworth, Sanofi Ventures.
Will AdvanCell IPO soon?
No public IPO plans have been announced for AdvanCell.
How can I track AdvanCell secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AdvanCell's secondary market activity and sign up for updates.